Dr Reddy's Launches Generic Bridion Injection in US
New Delhi: Dr Reddy's Laboratories on Tuesday said it has launched the generic version of Sugammadex injection indicated to reverse the effects of the muscle relaxants given during surgery in the United States.
The company has launched Sugammadex injection 200 mg/2 mL and 500 mg/5 mL single-dose vials, a generic equivalent of Bridion, in the US, Dr Reddy's Laboratories Ltd said in a statement.
Bridion is a registered trademark of Merck Sharp & Dohme BV, it added.
The launch expands the company's hospital portfolio and reinforces its commitment to improving patient access to affordable, high-quality medicines.
Sugammadex injection is a vertically integrated product manufactured through Dr Reddy's global supply network. The company has launched the product on the first day of generic availability in the US, it added.
Sugammadex Injection (100mg/ml) is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adult and pediatric patients aged 2 years and older undergoing surgery.
The Bridion brand (100mg/ml) had US sales of approximately USD 1.6 billion for the latest 12-month period ended May 2026, according to IQVIA National Sales Perspectives, the statement said.
